Last updated on February 2018

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive Low Tumor Burden Follicular Lymphoma (REFLECTIONS B328-06)


Brief description of study

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Clinical Study Identifier: NCT02213263

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

The Oncology Institute of Hope and Innovation
Lynwood, CA United States
0.72miles
  Connect »

Pfizer CT.gov Call Center

The Oncology Institute of Hope and Innovation
Downey, CA United States
4.7miles
  Connect »

Pfizer CT.gov Call Center

The Oncology Institute of Hope and Innovation
Long Beach, CA United States
4.95miles
  Connect »

Pfizer CT.gov Call Center

The Oncology Institute of Hope and Innovation
Montebello, CA United States
8.05miles
  Connect »

Pfizer CT.gov Call Center

Good Samaritan Imaging
Los Angeles, CA United States
9.24miles
  Connect »

Pfizer CT.gov Call Center

Los Angeles Hematology Oncology Medical Group
Los Angeles, CA United States
9.24miles
  Connect »

Pfizer CT.gov Call Center

Log Angeles Hematology Oncology Medical Group
Los Angeles, CA United States
9.84miles
  Connect »